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5.1  SUMMARY
B-Adrenerg ic  receptor  antagonis ts  remain
the cornerstone for therapy of cardiovascular
d isease for  a l ready more than th i r ty  years ,
despi te  a  cont inua l  change in  preva lence of
card iovascular  d isease,  popula t ion,  presenta-
t ion o f  the d isease,  prevent ion and many
other  fac tors .  Bet ter  unders tanding of  the
pathophys io logy of  card iovascular  d isease
provides for new concept and ideas for
t reatment .
Chapter is deal ing with the role of drugs
and the pharmaceut ica l  indust ry  in  the t reat -
ment  o f  cardrovascular  d iseases.  The concept
of  B-b lockade,  analys is  o f  the h is tor ica l  deve-
lopment  o f  the c l in ica l  indrcat ions and the
current views for the treatment of cardiovas-
cu lar  d iseases are descr ibed.  The complex i ty
of  regu la t ions for  c l in ica l  research are d iscus-
sed .
Chapter z presents an overview in the deve-
lopment of the concept of B-blockade over
the past 30 years. The presently avai lable B-
b lockers  are descrrbed.  The c l in ica l  ind ica-
t ions and l imi ta t ions,  ide e f fec ts  and cont ra-
rnd icat ions are d iscussed.  Less estab l ished
ind icat ions,  where theoret ica l ly  t reatment
wi th  B-b lockers  cou ld  be he lp fu l ,  but  ther r
use be ing inh ibr ted by fear  o f  s ide e f Íec ts ,  are
presenle0.
The in f luence of  the development  in  popula-
t ion,  concomi tant  d isease and concomi tant
treatment is evaluated. l t  is concluded that p-
b lockers  are s t i l l  va luable  drugs and that  they
offer effect ive and safe treatment for the
ind icated cardrovascular  d iseases.
ln Chapter J an overview of the l i terature on
c l in ica l  s tud ies wi th  b isopro lo l  is  documen-
ted. The benefiVrisk rat io of treatment with
brsoprolol was compared to the benefiVrisk
rat io  for  the B-b lockers  in  the srx t ies  and
seventies. ln cl inical studies the well-esta-
b l ished ind icat ions were tested under  the
current circumstances.
Chapter 4 documents our own cl inical studies
wi th  b isopro lo l  as  presented in  deta i l  in
appendices '1 - 13. The B-blocker bisoprolol
was evaluated Íor the treatment of cardio-
vascular  d iseases for  which the therapeut ic
value of B-blocker is well  establ lshed such as
angina pector rs ,  hyper tens ion and acute
myocardial infarct ion. Comparative tr ials with
establ ished B-blockers were performed. in
ind icat ions such as angina pector is  and acute
myocardial infarct ion, where placebo-con-
t ro l led t r ia ls  are e th ica l ly  no longer  jus t i Í ied.
In diseases where treatment with B-blockade
was less well  documented such as arrhyth-
mias, hyperthyroidism and anxiety, the vaÍue
of  B, -b lockade was eva luated.  The in Í luence
of B,-selectivi ty on side effects and the relat i-
ve cont ra- ind icat ions o f  hear t  fa i lu re ,  a t r ia l
f  i  b r i  I  lat ion an d r nterm it tent claudication were
chal lenged.  Poss ib le  new ind icat ions were
discussed. Intervention with B-blockade was
employed to  e luc idate pathophys io logrc
mechanrsms in hypertension and thyrotoxico-
s is  Sc ient i f rc  o l - r iec t ives which increased
knowledge of adrenoceptor functions were
explored us ing b isopro lo l  as  a  too l .
Comparative studies with drugs from other
classes were performed, rn order to evaluate
the posit ion of the B-blocker bisoprolol in
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compar i son  w i t h  mode rn  d rugs  l i ke  ACE ls .
New methods l ike heart rate variabi l i ty, auto-
ma t i c  b l oodp ressu re  reco rd ing  and  QKd
assessment were used for evaluation of the
eff icacy results and val idation of the method.
For each of the new studies several oblectives
were combined in a attempt to stat isfy both
scienti f ic and practical needs.
Our  s tud ies are descnbed in  deta i l  in  separa-
te  papers ,  documented in  the appendrces 1 -
1 3 .
For  the t reatment  o f  s tab le  exerc ise- induced
angina pectoris we confirmed the eff icacy of
B-b lockade in  reduc ing angina l  compla in ts
(Appendix r).  The value of 0,-select ivi ty was
evaluated in  th is  comparat ive t r ia l  w i th  a te-
no lo l .  B isopro lo l  1O mg was shown to  be
equipotent  to  100 mg atenolo l  for  the reduc-
t i on  o f  ang ina l  comp la in t s .
There are very few comparative studies in the
l i tera ture compar ing B-b lockers  and n i t ra tes,
thproínre \^/p .ómnared the effects of biso-L v v L ! v | | | t J '
pro lo l  and nr t ra tes in  s tab le  angina pector is  in
a cross-over study (Appendix z/.  B-Blockade
with bisoprolol was shown to be more effec-
t ive than vasodi la ta t ion wi th  n i t ra tes.
Because current ly  pat ients  wi th  acute myo-
card ia l  in farc t ion are in i t ia l ly  t reated wi th
thrombolys is ,  the safety  o f  th is  t reatment
wi th  added B-b lockers  to  thrombolysrs  In
acu te  myoca rd ia l  i n fa r c t i on  was  s tud ied
(Appendix 3). The benefi ts of B-blockade in
AMI a f ter  in i t ia l  thrombolys is  were found to
be unchanged compared to  the area before
thrombolys is  became standard therapy.
For  s t ra t i f ica t ion o f  h igh r isk  pat ients  who
would probably  prof i t  most  f rom the B-b lock-
ade in  acute myocard ia l  in farc t ion we analy-
sed features a t  base l ine and the i r  pred ic t ive
va lue for  an adverse outcome af ter  the i r
in farc t ion.  Only  fami ly  h is tory ,  in farc t  s ize and
heart rate correlated with an increased r isk
for  compl icat ions.  In a substudy the va lue of
the new methods for the analysis of heart
ra te  var iab i l i ty  for  r isk  s t ra t i f ica t ion was ana-
lysed lAppendix l .  Heart rate variabi l i ty was
demonstrated to be a powerful indicator for
pred ic t ing adverse outcome fo l lowing AMl .
The long-term effects of B-blockade on renal
funct ion and neurohormones were prev ious-
ly  unknown.  In  a  comparat ive t r ia l  w i th  a te-
no lo l  the in f luence of  b isopro lo l  on renal
funct ion and neurohormones was eva luated
over a period of six months (Appendíx 5).We
have shown that  b isopro lo l  and atenolo l  are
comparable  regard ing ther r  e f fec ts  on b lood
pressure,  hear t  ra te  and renal  haemodyna-
mics,  but  they d i f fer  s l ight ly  in  the i r  e f fec t  on
renal vascular esrstance.
In termi t tent  c laud icat ion isgenera l ly  cons ide-
red a re la t ive cont ra- ind icat ion for  B-b locka-
de. Patients with a combination of hyperten-
s ion and in termi t tent  c laud icat ion are usual ly
t reated wi th  vasodi la tors .  The h igh ly  p , -se lec-
t ive B-blocker bisoprolol was compared to
the angio tens in-conver t ing enzyme inh ib i tor
l isinopri l  in such patients (Appendix 6). We
found no impai rment  o f  walk ing d is tance
wi th  b isopro lo l  in  pat ients  wi th  hyper tens ion
and concomi tant  in termi t tent  c laud icat ion.
The changes in  per iphera l  b lood f low wi th
b isopro lo l  and l is inopr i l  a re  secondary  to  the
reduct ion in  b lood pressure.
Decrease of sexual function was documented
as a s ide ef fec t  o f  B-b lockade based upon
renor ts  No snec i f ic  s t r rdv to  assess the in f lu-
ence of  B-b lockade on male sexual  funct ion
has  p  rev ious l y  been  docu  men ted .  We
per formed a p lacebo-cont ro l led s tudy to  in-
67
vest igate  the in f luence of  b isopro lo l  on male
sexual functioning (Appendíx 7). Bisoprolol
was demonstrated an effect ive antihyperten-
sive drug with no sexual side effects. l t  seems
poss ib le  that  men on ant ihyper tens ive medi -
cat ion who a l ready have erect i le  d i f f icu l t ies
mrght benefi t  from bisoprolol treatment.
The va lue of  B-b lockade therapy in  hear t  Íar l -
ure  has recent ly  been accepted.  Espec ia l ly  the
init iat ion of B-blockers was expected to cause
adverse reactions. ln a comparative study of
b isopro lo l  w i th  propranolo l  we documented
the acute changes in  le f t  vent r icu lar  funct ton
in  pat ients  wi th  coronary  hear t  d isease and
heart fai lure (Appendix 8). We found no sta-
t is t ica l  s ign i f  icant  ev idence that  h igh doses oÍ
b i sop ro lo l  ( 10  mg)  no r  p rop rano lo l  ( 15  rg )
rn t ravenous ly  depressed myocard ia l  funct ion.
There is  a  potent ia l  ro le  for  B-b lockade in  the
t reatment  o f  a t r ia l  f ib r i l la t ion.  The reduct ron
of ventr icular response improves the left  ven-
t r icu lar  funct ion.  The in Í luence of  p-b lockade
on the at r ium i tse l f  is  less wel l  exp lored In  an
animal  model  we eva luated the in f luence of
B-b lockade on at r ia l  conduct ion in  a  compa-
rat ive study of bisoprolol and metoprolol
(Appendíx 9/. B-Blockade reduced the atr ial
conduc t i on ,  wh i ch  i s  no t  dependen t  on
mem brane-s tab i l  is ing proper t ies .
The efÍ icacy of bisoprolol for the treatment of
A-V nodal re-entry tachycardia was studied.
(Appendíx rc). A high percentage of termrna-
t ion (55%) and prevent ion o f  re- in i t ia t ion
(66%) of A-V nodal re-entry tachycardia was
found.  For  therapy of  hyper thyro id ism the
best  documented B-b locker  is  the non-se lec-
t ive B-b locker  propranolo l .  We compared the
eff icacy of bisoprolol to propranolol on the
reduction of heart rate, symptoms and car-
d iac output .  The la t ter  us ing non invas lve car -
diac output analysis (Appendíx n/. Bisoprolol
and propranolo l  were equal ly  e f fec t ive in
reduc ing the c l in ica l  symptoms,  hear t  ra te
and card iac output  in  pat ients  wi th  hyper thy-
ro id ism.
In the hyperventi lat ion syndrome the eff icacy
of  B-b lockers  was on ly  casual ly  documented.
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No placebo-control led study to assess the eff i-
cay of treatment with B-blockers in hyperven-
t i lat ion had been performed. We performed a
p lacebo-cont ro l led s tudy wi th  b isopro lo l
(Appendix n). Btsoprolol was shown to be
eÍfect ive for the maintenance of symptom
reduct ion in  pat ients  wi th  a  hypervent í la t ion
syndrome.  In  migrarne very  Íew p lacebo-con-
trol led studies to evaluate the eff icacy of B-
5.2  CONCLUSTONS
As rev iewed in  chapter  3  B-b lockers  remain
an ef fec t ive and wel l - to lera ted rug for  the
t reatment  o f  coronary  hear t  d isease and
hyper tens ion i  the cur rent  popula t ions o f
patients. This positron is confirmed by our
invest igat ions a  re fer red rn  chapter  4  and
the appendices.  Dur ing the c l in ica l  deve lop-
ment  o f  the B. -se lect ive B-b locker  b isopro lo l
we eva luated the c l in rca l  e f f icacy in  the wel l
es tab l ished ind icat ions.  The eÍ f icacy o Í  b iso-
pro lo l  in  coronary  hear t  d isease was compa-
rab le  to  o ther  B-b lockers .  ln  hyper tens ion the
side effects and inf luence on quali ty of l i fe
was comparable  to  or  bet ter  than the s ide
eÍ fect  pro f Í le  o f  o ther  B-b lockers  and drugs
f rom other  therapeut ic  lasses.
Fur thermore,  we exp lored poss ib le  new c l in i -
ca l  ind icat ions.  The h igh B, -se lect iv i ty  was
o v n o r t o d  t n  h r i n n  m n r o  c : f o t r r  : n d  l p q c  c i À ^L A V L t t L U  ( v  u r i l r V  r r r v r L  J q r L L y  q r r u  r L J J  ) l L l U
effects leadrng to more possibi lr tres of appl i-
ca t i ons  i n  m isce l l aneous  i nd rca t i ons .  l n
genera l ,  the s tud ies wi th  the B-b locker  b iso-
pro lo l  led to  the fo l lowing conc lus ions for  the
orrest ions ra ispd in  'A im of  the thes is '  on
page 1 6 .
b lockade on the prevent ion o f  migra ine
attacks have been reported. In a placebo-
control led study we evaluated the eff icacy of
b isopro lo l  in  the prevent ion o f  migra ine
at tacks and d iscussed the pathophys io log ica l
mechanism (Appendíx ry). Brsoprolol was
shown to be an effect ive drug for the pre-
vent ion o f  migra ine at tacks.
Does the h igh p1-se lect iv i ty  o f  b isopro lo l
o f fer  any c l in ica l  re levant  improvement
of  B-  b lockade?
In advance i t  was expected that  the h igh p, -
se lect iv i ty  o f  b isopro lo l  would  prov ide impro-
ved safety compared with other B-blockers.
In terms of eff icacy no cl inical relevant dif fe-
rence between b isopro lo l  and other  B-b lock-
ers  cou ld  be shown.  In  coronary  hear t  d isea-
se,  b isopro lo l  was demonst ra ted to  be an
effect ive B-blocker with an clear 24-hour
duration of act ion in the treatment of stable
e f f o r t  ang ina ,  as  demons t ra ted  by  t he
observed s ign i f icant  reduct ion in  hear t  ra te
and ra te  pressure product  dur ing exerc ise tes-
t ing.  B isopro lo l  and atenolo l  were equal ly
eÍÍect ive in the reduction of heart rate rn
acute myocard ia l  in farc t ion fo l lowing throm-
bolys is .
In  hyper tens ion,  o  c l in ica l  re levant  d i f feren-
ces between B-b lockers  cou ld  be shown in
terms of eff icacy. Several explanations may
be poss ib le  The p-b lock ing ef fec t  on the
adrenoceptors  may be dominant  to  anc i l la ry
proper t ies .  The se lect iv i ty  isdose-dependent ,
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the doses may not  have been adequate to
prove cl inical relevant dif ferences or in the
present  s tud ies the actua l  d i f ference rn
unopposed receptors may be so small  that
much  l a rge r  s tud res  wou ld  be  requ r red .
A teno lo l  and  b i sop ro lo l  had  comparab le
ef Íects  on renal  haemodynamics and neuro-
hormones wi th  the except ion o f  ren in  which
was more profoundly  suppressed by b isopro-
l o l .  The  h igh  Ê , - se lec t i v i t y  o f  b i sop ro lo l
offered opportunit ies for patients with relat i-
ve cont ra- ind icat ions such as smoking and
for  pat ients  wi th  concomi tant  d isease for
examole d iabetes mel l i tus  and obst ruct ive
pu lmona ry  l ung  d i sease .
Does the new B-b locker  b isopro lo l  o f fer
any therapeut ic  advantage for  card iovas-
cu la r  d i sease  compared  t o  t r ea tmen t
wi th  drugs f rom other  c lasses?
ln coronary artery disease, we did not expect
to f ind drfferences in eff icacy between drugs
from dif ferent classes. However, bisoprolol
was more effect ive than isosorbide dinrtrate
on the reduct ion o f  ang ina l  a t tacks and in  the
improvement  o f  exerc ise to lerance dur ing
bicycle exercise test ing in patients with stable
angina pector is .  In  the t reatment  o f  s i lent
ischaemia,  b isopro lo l  was demonst ra ted to
be more effect ive than monotherapy with
isosorbrdedin i t ra te  or  n i Íed ip ine.  In  the t reat -
ment  o f  coronary  hear t  d isease,  wi th  per iods
of  s i lent  ischaemia b isooro lo l  leads to  a  com-
p le te  reduct ion o Í  ischaemic ep isodes which
may lead to  the documented improvement  in
prog nos is .
In  hyper tens ion we compared the adverse
events  and the in f luence on qual i ty  o f  l i fe  o f
b isopro lo l  and drugs f rom other  c lasses.
Bisoprolol was an effect ive antihypertensrve
agent with no adverse effects on male sexual
function. Men who already suffer from erec-
t i le  d i f f  icu l t ies  re la ted to  ant ihyper tens ive
t reatment ,  might  even benef i t  f rom a change
to b isopro lo l  t reatment .  B isopro lo l  d id  not
impa i r  wa l k i ng  d i s tance  i n  pa t i en t s  w i t h
hyper tens ion and concomi tant  in termi t tent
c laudicat ion.  B, -se lect ive B-b lockers  l ike  b iso-
pro lo l  are  not  cont ra- ind icated in  pat ients
wi th  concomi tant  in termi t tent  c laud icat ion
The changes in  per iphera l  b lood f low wi th
b isopro lo l  and l is inopr i l  were secondary  to
the reduct ion in  b lood pressure.  The proven
eff icacy of B-blockers in coronary heart dis-
ease and secondary  prevent ion is  not  para l -
le led in  s tud ies wi th  n i t ra tes or  ca lc ium anta-
gonis ts .  In  hyper tens ion,  the proven benef r ts
of  B-b lockers  in  improved surv iva l  and equal
e f f icacy to  ACEI  and other  new compounds
favour the choice for B-blockers as f irst- l ine
treatment. Bisoprolol oífers a safety proÍ i le
whrch a l lows appl icat ions in  var ious s i tua-
Ï ions vr.,here other R-blOCkerS are leSS desira-
b le .
Can the new B-b locker  b isopro lo l  be used
in  the t reatment  o f  recent ly  recognised
symptoms and/or  new c l in ica l  s i tuat ions?
In addi t ion to  the s tud ies in  coronary  hear t
d isease and hyper tens ion we exp lored new
si tuat ions.  For  acute myocard ia l  in farc t ion
t reated wi th  thrombolys is ,  the va lue of  B-
b lockade dur ing the acute phase remains
unchanged.  In  these cr rcumstances analys is
of  hear t  ra te  var iab i l i ty  may be usefu l  in  r isk
st ra t i f ica t ion.  In  new ind icat ions e .9 . ,  a t r ia l
f ibr i l lat ion, the effects of bisoprolol on heart
rà1c  \^ /p rp  romnarah lc  ïn  mptnnro lo l  The'  '  ' !  \ v y '  v ' v ' .
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mrld class-l  effect of metoprolol did not play
a role in the rate reducinq effects of B-block-
ade rn  a t r ia l  f ib r i l la t ion.
B isopro lo l  appears  to  be promis ing for  the
hear t  ra te  cont ro l  in  chron ic  a t r ia l  f ib r i l la t ion
and in  the terminat ion and prevent ion o f  R-V
nodal re-entry tachycardia.
Bisoprolol seems to be effect ive in heart farl-
ure, although, the exact prof i le of patients
has to  be ident i f ied in  ungoing s tud ies.
Can the new B-b locker  b isopro lo l  safe ly
be g iven in  less wel l  recognised c l in ica l
condi t ions for  B-b lockade?
In severa l  less wel l  recognised ind icat ions,
comparative tr ials to assess the eÍf icacy of B-
blockers were lacking. ln patients with hyper-
thyro idrsm,  b isopro lo l  and propranolo l  were
equal ly  e f fec t ive rn  reduc ing the c l in ica l
symptoms and heart rate. This eÍfect appears
to be not so much due to a decreased pro-
duct ron of  thyro id  hormones,  as to  suppress-
ion o f  the sympath ic  nervous system,  s t imu-
la ted by thyrotox icos is .  In  ind icat ions,  uch as
anx ie ty  and migra ine where t reatment  wi th
B-blocker is theoretical ly indicated, but prac-
t ical ly lnhibited for fear of side effects, biso-
prolol was shown to be effect ive and safe in
placebo-control led and comparative studies.
B isopro lo l  can be successfu l ly  used for  t reat -
ment of symptoms of anxiety. The results of
our study in patients with hyperventi lat ion,
demonstrate that bisoprolol is effect ive in the
ma Ín tenance  o f  symp tom reduc t i on  i n
patients with a hyperventi lat ion syndrome.
Bisoprolol is an effect ive drug Íor the preven-
t ion of migraine attacks. The safety offered
by the high B,-selectivi ty of brsoprolol makes
t reatment  o f  these symptoms and condr t ions
feas ib le .
